You are here: Industry Insights > BAN2401

News List

Novel anti-amyloid drug BAN2401 enters Phase III trial in Alzheimer’s patients europeanpharmaceuticalreview
July 23, 2020
BAN2401 will be tested in various stages of Alzheimer’s disease progression to assess if it can slow the progression of cognitive decline.
Eisai, Biogen move Alzheimer’s treatment into Phase III pharmatimes
March 27, 2019
Eisai and Biogen have announced that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401, for use in patients with early Alzheimer's disease.
Eisai, Biogen’s Alzheimer’s candidate shows promise in PhII trial pharmatimes
July 09, 2018
At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease.
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint biospectrumasia
December 26, 2017
Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in patients with prodromal or mild Alzheimer’s disease (collectively known as early Alzheimer’s disease) and with positive biomarkers for brain amyloid pathology